{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": -0.06, "bookValue": -0.12, "priceToBook": -10.509583, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "currency": "EUR", "financialCurrency": "USD", "regularMarketOpen": 1.26115, "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "1.26115 - 1.26115", "fiftyTwoWeekHighChange": 0.0, "fiftyTwoWeekHighChangePercent": 0.0, "fiftyTwoWeekLow": 1.26115, "fiftyTwoWeekHigh": 1.26115, "earningsTimestamp": 1677618000, "earningsTimestampStart": 1691438400, "earningsTimestampEnd": 1691784000, "trailingAnnualDividendRate": 0.0, "priceHint": 4, "marketState": "CLOSED", "regularMarketChange": 1.26115, "regularMarketTime": 1683905701, "regularMarketDayHigh": 1.26115, "regularMarketDayRange": "1.26115 - 1.26115", "regularMarketDayLow": 1.26115, "regularMarketVolume": 22400, "regularMarketPreviousClose": 0.0, "bid": 0.0, "ask": 0.0, "fullExchangeName": "LSE", "regularMarketPrice": 1.26115, "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "esgPopulated": false, "exchange": "LSE", "shortName": "NORTHWEST BIOTHERAPEUTICS INC N", "longName": "Northwest Biotherapeutics, Inc.", "messageBoardId": "finmb_1342115", "market": "gb_market", "symbol": "0K95.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "4800 Montgomery Lane", "address2": "Suite 800", "city": "Bethesda", "state": "MD", "zip": "20814", "country": "United States", "phone": "240 497 9024", "website": "https://www.nwbio.com", "industry": "", "sector": "", "longBusinessSummary": "Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.", "fullTimeEmployees": 22, "companyOfficers": [{"maxAge": 1, "name": "Ms. Linda F. Powers J.D.", "age": 66, "title": "Chairperson, CEO, Pres, CFO & Chief Accounting Officer", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": {"raw": 1100000, "fmt": "1.1M", "longFmt": "1,100,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 43327644, "fmt": "43.33M", "longFmt": "43,327,644"}}, {"maxAge": 1, "name": "Dr. Alton L. Boynton Ph.D.", "age": 77, "title": "Founder, Chief Scientific Officer, Sec. & Director", "yearBorn": 1945, "fiscalYear": 2022, "totalPay": {"raw": 450000, "fmt": "450k", "longFmt": "450,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 4597314, "fmt": "4.6M", "longFmt": "4,597,314"}}, {"maxAge": 1, "name": "Dr. Marnix L. Bosch M.B.A., MBA, Ph.D.", "age": 63, "title": "Chief Technical Officer", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 597500, "fmt": "597.5k", "longFmt": "597,500"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 16162125, "fmt": "16.16M", "longFmt": "16,162,125"}}, {"maxAge": 1, "name": "Mr. Leslie J. Goldman", "age": 77, "title": "Sr. VP & Gen. Counsel", "yearBorn": 1945, "fiscalYear": 2022, "totalPay": {"raw": 825000, "fmt": "825k", "longFmt": "825,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 27374524, "fmt": "27.37M", "longFmt": "27,374,524"}}, {"maxAge": 1, "name": "Ms. Jean M. Davis", "age": 50, "title": "Chief Information Officer", "yearBorn": 1972, "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David  Innes", "title": "VP of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Pankaj R. Shah C.A., CPA", "title": "Financial Controller", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}